Tristan Richard Gordon Sillars
Director de Operaciones en Arquer Diagnostics Ltd. .
Cargos activos de Tristan Richard Gordon Sillars
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Arquer Diagnostics Ltd.
 Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Director/Miembro de la Junta | - | - |
| Director de Operaciones | - | - | |
| Director Financiero/CFO | - | - |
Historial de carrera de Tristan Richard Gordon Sillars
Antiguos cargos conocidos de Tristan Richard Gordon Sillars.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| KPMG Transaction Services Group | Corporate Officer/Principal | - | - |
Estadísticas
Internacional
| Reino Unido | 3 |
Operativa
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
| Director of Finance/CFO | 1 |
Sectorial
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Arquer Diagnostics Ltd.
Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
| KPMG Transaction Services Group |
